
WASOG

World Association for Sarcoidosis and **O**ther Granulomatous Disorders



WASOG

1987




Dr. Gerry James




Prof. Om Sharma

Cause of sarcoidosis: combination



Prof. om Sharma: the teacher Story of 6 blind men and an elephant



It's all a matter of viewpoint

© Mattioli 1885

THE WASOG SARCOIDOSIS ORGAN ASSESSMENT INSTRUMENT: AN UPDATE OF A PREVIOUS CLINICAL TOOL

M.A. Judson¹, U. Costabel², M. Drent³, A. Wells⁴, L. Maier⁵, L. Koth⁶, H. Shigemitsu¹, D.A. Culver⁵, J. Gelfand⁶, D. Valeyre⁶, N. Sweiss¹⁰, E. Crouser¹¹, A. S. Morgenthau¹², E.E. Lower¹³, A. Azuma¹⁴, M. Ishihara¹⁵, S. Morimoto¹⁶, T. Yamaguchi¹⊓, N. Shijubo¹⁵, J.C. Grutters¹⁰, M. Rosenbach²⁰, H.P. Li²¹, P. Rottoli²², Y. Inoue²³, A. Prasse²⁴, R.P. Baughman¹³, The WASOG Sarcoidosis Organ Assessment Instrument Investigators*

¹Albany Medical College; Albany, New York USA; ²Ruhrlandklinik, University Hospital, University Duisburg-Essen, Essen, Germany; ³Gelderse Vallei Hospital Ede; Maastricht University, Maastricht, The Netherlands; ⁴Royal Brompton Hospital, London; ⁵National Jewish Health, Denver, Colorado USA; ⁶University of California, San Francisco, San Francisco, CA USA; ⁷University of Southern California Keck School of Medicine, Los Angeles, California USA; ⁸Cleveland Clinic, Cleveland, Ohio USA; ⁹AP-HP, Hôpital Avicenne, Université Paris 13, Sorbonne Paris Cité, France; ¹⁰University of Illinois College of Medicine at Chicago, Chicago, Illinois USA; ¹¹The Ohio State University Medical Center, Columbus, Ohio USA; ¹²Icahn School of Medicine at Mount Sinai; New York, New York USA; ¹³University of Cincinnati Medical Center; Cincinnati, OH, USA; ¹⁴Nippon Medical School, Tokyo, Japan; ¹⁵Department of Ophthalmology and Visual Science, Yokohama City, Japan; ¹⁶Aoyama General Hospital, Tokyo, Japan; ¹⁷Japan Railway Tokyo General Hospital, Tokyo, Japan; ¹⁸JR Sapporo Hospital, Sapporo, Japan; ¹⁹St. Antonius Hospital, Utrecht, The Netherlands; ²⁰University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania USA; ²¹Tongji University, School of Medicine, Shanghi, China; ²⁰Azienda Ospedaliera Universitaria

REVIEW



Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide

Johanna P. Cremers^a, Marjolein Drent^{a,b}, Aalt Bast^b, Hidenobu Shigemitsu^{c,d}, Robert P. Baughman^e, Dominique Valeyre^{f,g}, Nadera J. Sweiss^b, and Tim L. Jansenⁱ


Glucocorticosteroids

- Glucocorticosteroids
 - First-line treatment in systemic sarcoidosis
 - Most commonly used
- Alternative second-line agents important
 - Steroid-resistance
 - Steroid-induced side-effects
 - Steroid-sparing



Case: 33-year-old man







September 2008



January 2009

Treatment
MTX 12.5 mg once a week orally
Folic acid 5 mg once a week
ICD

Case: 38-year-old woman



Before MTX




After MTX

Treatment

MTX 12.5 mg once a week subcutaneous Folic acid 5 mg twice a week Prednisone 7.5 mg daily orally

Case: 36-year-old man



HRCT before MTX



HRCT after 6 months MTX


Treatment

MTX 12.5 mg once a week orally Folic acid 5 mg once a week Prednisone 10 mg daily

Possible misconceptions

- 'MTX is not useful as anti-inflammatory agent due to major toxicity'
 - 11% of pulmonologists do not prescribe MTX
 - In sarcoidosis discontinuation of MTX only 0-10%
 - GI complaints most reported reason
 - In RA MTX less frequently discontinued than other DMARDs ¹
- 'MTX orally is as effective as subcutaneously'
 - Only 42% of experts prescribed MTX subcutaneous in GI toxicity
 - Parenteral MTX higher effectiveness en less GI toxicity 2
 - Other option: splitting oral dose ²
- 'Males with child wish need to stop MTX because of the risk of malformations/teratogenicity'
 - We don't know yet

Conclusions



- MTX is first-choice second-line agent in sarcoidosis
- optimization of its use is important
- multinational recommendations serve to promote this
- future research
 - establishment possible misconceptions
 - revealing mechanism of antiinflammatory action


Everything you've always wanted to know about the use of MTX in sarcoidosis...

Help is at hand.
There's an app for that!




The app was developed on behalf of the ild care foundation (www.ildcare.eu) and the WASOG.

You can find it in the Apple Store or Google Play Store. Download it for free!



Pharmacotherapeutic options in sarcoidosis: How can we improve them?





American Thoracic Society Documents

An Official American Thoracic Society Clinical Practice Guideline: The Clinical Utility of Bronchoalveolar Lavage Cellular Analysis in Interstitial Lung Disease

Keith C. Meyer, Ganesh Raghu, Robert P. Baughman, Kevin K. Brown, Ulrich Costabel, Roland M. du Bois, Marjolein Drent, Patricia L. Haslam, Dong Soon Kim, Sonoko Nagai, Paola Rottoli, Cesare Saltini, Moisés Selman, Charlie Strange, and Brent Wood, on behalf of the American Thoracic Society Committee on BAL in Interstitial Lung Disease

THIS OFFICIAL CLINICAL PRACTICE GUIDELINE OF THE AMERICAN THORACIC SOCIETY (ATS) WAS APPROVED BY THE ATS BOARD OF DIRECTORS, JANUARY 2012

American Thoracic Society Documents

An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias

William D. Travis*, Ulrich Costabel*, David M. Hansell*, Talmadge E. King, Jr.*, David A. Lynch*, Andrew G. Nicholson*, Christopher J. Ryerson*, Jay H. Ryu*, Moisés Selman*, Athol U. Wells*, Jurgen Behr, Demosthenes Bouros, Kevin K. Brown, Thomas V. Colby, Harold R. Collard, Carlos Robalo Cordeiro, Vincent Cottin, Bruno Crestani, Marjolein Drent, Rosalind F. Dudden, Jim Egan, Kevin Flaherty, Cory Hogaboam, Yoshikazu Inoue, Takeshi Johkoh, Dong Soon Kim, Masanori Kitaichi, James Loyd, Fernando J. Martinez, Jeffrey Myers, Shandra Protzko, Ganesh Raghu, Luca Richeldi, Nicola Sverzellati, Jeffrey Swigris, and Dominique Valeyre; on behalf of the ATS/ERS Committee on Idiopathic Interstitial Pneumonias

http://www.wasog.org



Sarcoidosis and ild around the world

To inform you about sarcoidosis and other ild in different countries we asked colleagues to summarize the prevalence, the research and important websites, etc. We would like to ask your collaboration:

If a column of your home country is not available yet, feel free to write a nice one concerning this particular item (sarcoidosis and/or ild) in your own country.

- 4						li	
- 20		m.	÷	-	-	1 1	-
Aut	ы	100	н	г,	м		100
1	we.	mati-	-		we	-	-

Belgium

Brasil

China

Croatia

Finland

France

Germany

Greece

Iceland

India

Ireland

srael

Italy

Japan

Korea

Mexico

Netherlands

New Zealand

Poland

Russia

Serbia

South Africa

Spain

Sweden

USA

Join WASOG (World Association of Sarcoidosis and Other Granulomatous Diseases)

Why join WASOG?

- WASOG organizes meetings for physicians involved in interstitial lung diseases especially sarcoidosis and other granulomatous diseases
- educates interested people
- offers the opportunity to exchange scientific experiences next WASOG meeting: June 15-18, 2011 in Maastricht, the Netherlands

Benefits of your WASOG membership?

- get information, keep updated
- network
- reduced fees for WASOG meetings
- get full access to members' only material (e.g. the members roster and official documents)
- have access to the full paper PDFs published in Sarcoidosis, Vasculitis and Diffuse Lung Diseases, the official journal of WASOG (Editors in Chief: R. Baughman, V. Poletti & C. Saltini)

Joining WASOG is easy!

Benefits of your WASOG membership?



Have access to the full paper PDFs published in Sarcoidosis, Vasculitis and Diffuse Lung Diseases, official journal of WASOG Editors in Chief:

- R. Baughman
- V. Poletti
- & C. Saltini

Married although AIPO - MINER

© Mattioli 1885


THE WASOG SARCOIDOSIS ORGAN ASSESSMENT INSTRUMENT: AN UPDATE OF A PREVIOUS CLINICAL TOOL

M.A. Judson¹, U. Costabel², M. Drent³, A. Wells⁴, L. Maier⁵, L. Koth⁶, H. Shigemitsu¹, D.A. Culver⁵, J. Gelfand⁶, D. Valeyre⁶, N. Sweiss¹⁰, E. Crouser¹¹, A. S. Morgenthau¹², E.E. Lower¹³, A. Azuma¹⁴, M. Ishihara¹⁵, S. Morimoto¹⁶, T. Yamaguchi¹⊓, N. Shijubo¹⁵, J.C. Grutters¹⁰, M. Rosenbach²⁰, H.P. Li²¹, P. Rottoli²², Y. Inoue²³, A. Prasse²⁴, R.P. Baughman¹³, The WASOG Sarcoidosis Organ Assessment Instrument Investigators*

¹Albany Medical College; Albany, New York USA; ²Ruhrlandklinik, University Hospital, University Duisburg-Essen, Essen, Germany; ³Gelderse Vallei Hospital Ede; Maastricht University, Maastricht, The Netherlands; ⁴Royal Brompton Hospital, London; ⁵National Jewish Health, Denver, Colorado USA; ⁶University of California, San Francisco, San Francisco, CA USA; ⁷University of Southern California Keck School of Medicine, Los Angeles, California USA; ⁸Cleveland Clinic, Cleveland, Ohio USA; ⁹AP-HP, Hôpital Avicenne, Université Paris 13, Sorbonne Paris Cité, France; ¹⁰University of Illinois College of Medicine at Chicago, Chicago, Illinois USA; ¹¹The Ohio State University Medical Center, Columbus, Ohio USA; ¹²Icahn School of Medicine at Mount Sinai; New York, New York USA; ¹³University of Cincinnati Medical Center; Cincinnati, OH, USA; ¹⁴Nippon Medical School, Tokyo, Japan; ¹⁵Department of Ophthalmology and Visual Science, Yokohama City, Japan; ¹⁶Aoyama General Hospital, Tokyo, Japan; ¹⁷Japan Railway Tokyo General Hospital, Tokyo, Japan; ¹⁸JR Sapporo Hospital, Sapporo, Japan; ¹⁹St. Antonius Hospital, Utrecht, The Netherlands; ²⁰University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania USA; ²¹Tongji University, School of Medicine, Shanghi, China; ²⁰Azienda Ospedaliera Universitaria

Negative vicious circle of physical deconditioning:


disabling symptoms in sarcoidosis can reduce daily physical activities, cause general deconditioning and reduced QOL (adapted from Swigris et al.)



Swigris JJ, et al. Pulmonary rehabilitation in idiopathic pulmonary fibrosis: a call for continued investigation.

Respir Med 2008; 102:1675-80.

Vague complaints like fatigue hard to objectify



Online Questionnaires available

Fatigue Assessment Scale (FAS)

Online form English

Download PDF File English

Small fibre neuropathy screening list (SFNSL)

Online form English

Download PDF File English

King's Sarcoidosis Questionnaire

Online form English

Quality of life (WHOQOL-100 USA)

Download PDF File English

WHOQOL-Bref UK

Download PDF File English

CFQ (Cognitive Failure Questionnaire)



neurosarcoidosis registry

HOME SARCOIDOSIS REGISTRY PAT

PATIENT

PHYSICIAN

LINKS


FAQ'S

NEWS

ABOUT US

Professional





Login

For registered users:

Username:

Password:

Login

Password forgotten? Click here

Professional:

Enroll a patient

Patient:

I want to join

Recent News

(2014/5/27 (6 bits) Website online


3rd WASOG-BAL meeting: Turkey, October 8-11, 2014

Kusadasi, a resort town near Izmir and ancient Ephesus











More information about the WASOG-BAL





www.wasogbal2014.org